Page 9 - 2020_01-Haematologica-web

haematologica Journal of the Ferrata Storti Foundation
Letters to the Editor
Letters are available online only at www.haematologica.org/content/105/1.toc
e1 Novel variants in Iranian individuals suspected to have inherited red blood cell disorders, including bone marrow failure syndromes Maryam Neishabury et al.
http://www.haematologica.org/content/105/1/e1
e5 Erdheim-Chester disease with concomitant Rosai-Dorfman like lesions: a distinct entity mainly driven by MAP2K1 Jérôme Razanamahery et al.
http://www.haematologica.org/content/105/1/e5
e9 Molecular minimal residual disease negativity and decreased stem cell mobilization potential predict excellent outcome after autologous transplant in NPM1 mutant acute myeloid leukemia
Alvaro de Santiago de Benito et al.
http://www.haematologica.org/content/105/1/e9
e13 Long-term follow-up of a trial comparing post-remission treatment with autologous or allogeneic bone marrow transplantation or inten- sive chemotherapy in younger acute myeloid leukemia patients
Frédéric Baron et al.
http://www.haematologica.org/content/105/1/e13
e17 Bafilomycin A1 targets patient-derived CD34+CD19+ leukemia stem cells Li Xu et al.
http://www.haematologica.org/content/105/1/e17
e22 Ibrutinib reduces obinutuzumab infusion-related reactions in patients with chronic lymphocytic leukemia and is associated with changes in plasma cytokine levels
Juliana Velez Lujan et al. http://www.haematologica.org/content/105/1/e22
e26 A phase 1 trial of alisertib and romidepsin for relapsed/refractory aggressive B-cell and T-cell lymphomas Paolo Strati et al.
http://www.haematologica.org/content/105/1/e26
e29 Dose-adjusted EPOCH regimen as first-line treatment for non-Hodgkin lymphoma-associated hemophagocytic lymphohistiocytosis: a sin- gle-arm, open-label, phase II trial
Jin-Hua Liang et al. http://www.haematologica.org/content/105/1/e29
e33 Prognostic value of FDG-PET in patients with mantle cell lymphoma: results from the LyMa-PET Project Clément Bailly et al.
http://www.haematologica.org/content/105/1/e33
e37 Pre-treatment CD38-positive regulatory T cells affect the durable response to daratumumab in relapsed/refractory multiple myeloma patients
Akihiro Kitadate et al. http://www.haematologica.org/content/105/1/e37
Comments
Comments are available online only at www.haematologica.org/content/105/1.toc
e41 Prognostic value of 18F-FDG-PET in patients with mantle cell lymphoma: results from the LyMa-PET Project Eric Laffon and Roger Marthan
http://www.haematologica.org/content/105/1/e41
e42 Reply to E. Laffon et al. Clément Bailly et al.
http://www.haematologica.org/content/105/1/e42
Haematologica 2020; vol. 105 no. 1 - January 2020 http://www.haematologica.org/